COVID-19: Vaccine immunogenicity, interleukin-6 inhibitors, mucormycosis

Kieran Walsh, clinical director at BMJ, asks editors from BMJ Learning and BMJ Best Practice to summarise the latest clinical guidance related to Covid-19. Abigail Davis, GP and section editor, covers the latest evidence around vaccine immunogenicity in different immunosuppressed populations, as well as the use of interleukin-6 inhibitors in COVID-19 patients. And Emma Scott, section editor, updates us on mucormycosis, or black fungus infection in COVID-19 patients. For more, see: BMJ Best Practice's topic on COVID-19: bestpractice.bmj.com/topics/en-gb/3000168 BMJ Learning module on COVID-19 rapid guideline on critical care (NICE): new-learning.bmj.com/course/10065100 BMJ Learning COVID-19 in primary care module: new-learning.bmj.com/course/10065230 Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00676-0/fulltext Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19: https://www.nejm.org/doi/full/10.1056/NEJMoa2100433 WHO Therapeutics and COVID-19: living guideline: https://app.magicapp.org/#/guideline/nBkO1E/section/LrV7OL Indian Council of Medical Research advice on mucormycosis: https://www.icmr.gov.in/pdf/covid/techdoc/Mucormycosis_ADVISORY_FROM_ICMR_In_COVID19_time.pdf